Supplementary Figures 1 - 5, Table 1 from Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an <i>In Vivo</i> Model of <i>NRAS</i>-Mutant Melanoma

PDF file - 295K, Supplemental Figure 1: XL888 (0.3 μM) treatment induces the nuclear accumulation of FOXO3a. Supplemental Figure 2: XL888 decreases Mcl-1 mRNA expression in NRAS mutant melanoma. Supplemental Figure 3: BAK is not required for XL888-mediated apoptosis. Supplemental Figure 4: The BH3 family protein inhibitor ABT-737 enhances the pro-apoptotic effects of XL888 in the WM1366 and WM1361A cell lines. Supplemental Figure 5: The effects of XL888 (300nM) and ABT-737 (1 μM) on the viability of NRAS mutant melanoma spheroids. Supplemental Table 1: List of heat shock proteins used on the LC-MRM by UniPROT ID and gene name.</p

Supplementary Materials, Tables 1-2, Figures 1-11 from The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms

PDF file - 1.0MB</p

Supplementary Video 4 from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

Supplementary Video 4</p

Supplementary Figures from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

Supplementary Figures and Legends</p

Supplementary Tables from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

Supplementary Tables</p

CCR Translation for This Article from The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms

CCR Translation for This Article from The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanism

Supplementary Video 2 from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

Supplementary Video 2</p

Supplementary Video 7 from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

Supplementary Video 7</p

Supplementary Video 3 from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

Supplementary Video 3</p

Supplementary Data from BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells

Supplemental Figure 1. Temporal regulation and the effect of combination of B-raf inhibitor on M6PR expression. Supplemental Figure 2. Effect of combination of B-raf and MEK inhibitors on M6PR expression. Supplemental Figure 3. WM35 cells resistant to PLX4720. Supplemental Figure 4. Effect of M6PR overexpression and deletion on melanoma cell sensitivity to PLX4720 in MTT test. Supplemental Figure 5. Expression of surface molecules on melanoma cells with manipulated expression of M6PR. Supplemental Table 1 Clinical characteristics of patients enrolled to the study Supplemental Table 2. Grade 3+ Adverse Events in treated patients</p